Assess the Oral Bioavailability of New ABT-263 Formulations

Summary

This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors will be enrolled in this study.

Timeline

Start

2008-08

Primary completion

2010-08

Completion

—

Drugs

Indications